Survodutide MASH Data — PatSnap Eureka
Survodutide (BI 456906): Search the MASH & Liver Fibrosis Patent Landscape
Boehringer Ingelheim's GLP-1/glucagon receptor dual agonist is advancing through Phase IIb/III in MASH — a disease area of high unmet need and intense competitive activity. Run your own patent and literature search on PatSnap Eureka to surface the intelligence you need.
Search Dimensions Executed for Survodutide MASH Intelligence
Three targeted search dimensions were executed across six patent jurisdictions for survodutide (BI 456906), Boehringer Ingelheim's investigational GLP-1/glucagon dual agonist in MASH and liver fibrosis.
Core Mechanism: GLP-1/Glucagon Dual Agonism
Search terms: GLP-1/glucagon dual agonism, survodutide, BI 456906, hepatic steatosis, MASH mechanism. Executed across US, EP, WO, CN, JP, KR patent jurisdictions.
0 Records RetrievedDisease-Specific Application: MASH Phase IIb & Liver Fibrosis
Search terms: MASH Phase IIb, liver fibrosis endpoints, NASH histology, NAS score, fibrosis stage. Targeted clinical development and histology endpoint literature.
0 Records RetrievedAssignee & Combination IP: Boehringer Ingelheim
Search terms: Boehringer Ingelheim, dual agonist combination, GLP-1 glucagon receptor agonist IP. Targeted assignee-level patent portfolio and combination therapy filings.
0 Records RetrievedWhy No Records Were Retrieved — And What To Do Next
Survodutide (BI 456906) is Boehringer Ingelheim's investigational GLP-1 receptor/glucagon receptor dual agonist, representing a mechanistically differentiated approach to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis — a disease area of high unmet need and intense competitive activity.
The data retrieval process returned no results across all search dimensions executed for this query. This means no patents from any jurisdiction (US, EP, WO, CN, JP, KR) were retrieved relating to survodutide, BI 456906, or Boehringer Ingelheim's GLP-1/glucagon dual agonist program. No academic papers were retrieved covering survodutide pharmacology, MASH clinical trial design, liver histology endpoints, or fibrosis biomarker data.
Additionally, no combination therapy, emerging directions, or IP strategy signals could be extracted from the dataset. Generating content under these conditions would constitute fabrication — a practice this analytical framework explicitly prohibits. Analysts should consult ClinicalTrials.gov directly for NCT identifiers associated with the BI 456906 MASH Phase IIb program, and review conference abstract repositories from EASL and AASLD meetings (2023–2025).
The PatSnap analytics platform provides direct access to IPC-filtered patent searches, assignee portfolio analysis, and clinical literature integration that can surface this intelligence when the right query terms are applied.
Recommended Search Dimensions for Survodutide & MASH Intelligence
These four source categories are recommended for analysts, researchers, or IP strategists seeking survodutide intelligence, based on where this data is most likely to reside.
Patent Database Coverage by Jurisdiction
Recommended patent databases for survodutide (BI 456906) and Boehringer Ingelheim GLP-1/glucagon IP, filtered to IPC classes A61K38 and A61P1/16.
Clinical Literature Sources for MASH Phase IIb/III Data
Recommended clinical databases and conference repositories where survodutide Phase IIb/III data for MASH and liver fibrosis endpoints is most likely to be found.
Four Approaches for Survodutide & MASH Intelligence Retrieval
For analysts, researchers, or IP strategists seeking survodutide intelligence, the following approaches are recommended based on where this data is most likely to reside.
Retry With Alternate Terminology
Use alternate search terms: BI 456906, dual GLP-1/glucagon receptor agonist, MASH fibrosis Phase III, liver steatosis dual incretin, and Boehringer Ingelheim NASH. These five terms are recommended as the primary alternate query set for this topic.
Query Patent Databases Directly
Search USPTO, EPO Espacenet, and WIPO PatentScope using assignee "Boehringer Ingelheim" filtered to IPC classes A61K38 (peptide therapeutics) and A61P1/16 (liver disease).
How to Build a Survodutide Patent & Literature Search
A structured four-step approach for IP strategists and R&D analysts seeking to map the survodutide (BI 456906) patent landscape and MASH clinical data.
Ready to Run the Search Yourself?
PatSnap Eureka integrates patent, literature, and clinical data in a single AI-powered search interface — built for life sciences R&D and IP teams.
Survodutide MASH & Liver Fibrosis — key questions answered
Survodutide (BI 456906) is Boehringer Ingelheim's investigational GLP-1 receptor/glucagon receptor dual agonist, representing a mechanistically differentiated approach to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, a disease area of high unmet need and intense competitive activity.
Analysts should directly query patent databases including USPTO, EPO Espacenet, and WIPO PatentScope using assignee "Boehringer Ingelheim" filtered to IPC classes A61K38 (peptide therapeutics) and A61P1/16 (liver disease).
Search clinical literature databases including PubMed, ClinicalTrials.gov, The Lancet, and NEJM for trial identifiers associated with the MASH Phase IIb program (e.g., NCT identifiers for BI 456906). Review conference abstract repositories from EASL, AASLD, and ENDO meetings (2023–2025), where Phase IIb/III data for dual agonists in MASH have been presented.
Recommended alternate terminology includes: BI 456906, dual GLP-1/glucagon receptor agonist, MASH fibrosis Phase III, liver steatosis dual incretin, and Boehringer Ingelheim NASH.
Conference abstract repositories from EASL, AASLD, and ENDO meetings (2023–2025) are recommended sources where Phase IIb/III data for dual agonists in MASH have been presented.
Relevant IPC classes include A61K38 (peptide therapeutics) and A61P1/16 (liver disease), which should be used when filtering patent database searches for Boehringer Ingelheim's dual agonist program.
Still have questions? Let PatSnap Eureka search patents and literature to answer them for you.
Ask PatSnap Eureka About MASHSearch Survodutide & MASH Patents Across All Jurisdictions
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — including life sciences teams tracking GLP-1/glucagon dual agonist IP in MASH and liver fibrosis.
References
- ClinicalTrials.gov — NCT identifiers for BI 456906 MASH Phase IIb program
- PubMed — Survodutide pharmacology and MASH clinical literature
- EASL (European Association for the Study of the Liver) — Conference abstract repositories 2023–2025
- AASLD (American Association for the Study of Liver Diseases) — The Liver Meeting abstract repositories 2023–2025
- WIPO PatentScope — PCT/WO patent filings, IPC A61K38 and A61P1/16
- EPO Espacenet — European patent database, Boehringer Ingelheim dual agonist filings
- USPTO — US patent database, peptide therapeutics and liver disease IPC classes
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.